THE-NATURE-CONSERVANCY
22.4.2024 08:01:25 CEST | Business Wire | Press release
Today, the Government of Mongolia, The Nature Conservancy (TNC), and others announced the launch of Eternal Mongolia – a Project Finance for Permanence (PFP) initiative that will deliver lasting conservation and sustainable community development for the Central Asian country whose vast steppe represents our planet’s last great tract of intact temperate grassland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240421544883/en/
Mongolia's Nationally Protected area, Toson Hulstai. ©TNC
Eternal Mongolia is a negotiated partnership that will deliver USD $198 million of new investment over 15 years to support Mongolia’s ambitious goals and deliver lasting conservation and sustainable community development in and around protected areas. This includes a USD $71 million transition fund from private and other global donor sources. This transition fund will accelerate Mongolia’s conservation and community development goals, while providing time to develop sustainable financing mechanisms to ensure protected areas can be managed sustainably in the long-term and that Mongolian people benefit from nature, now and for the future.
Eternal Mongolia will dramatically expand and strengthen the effectiveness of the country’s entire National Protected Area network, support sustainable herding practices, invest in the sustainable tourism industry, and set an unprecedented example to the rest of the world about the value of land and freshwater conservation.
The PFP will support local community-driven proposals to safeguard an additional 14.4 million hectares of Mongolia’s lands and waters including intact grasslands, forests, deserts, wetlands and rivers; strengthen the management of all of Mongolia’s National Protected Areas covering 47 million hectares; and extend sustainable and climate-resilient community-managed practices to 34 million hectares outside protected areas.
Mongolia established itself as a world conservation leader 30 years ago by committing to a vision revolutionary for its time: to protect 30% of its lands—a goal now shared around the world. Eternal Mongolia unlocks all the funding and policy commitments needed for Mongolia to ensure its 30% conservation target will be met by 2030 while providing a secure and economic future for Mongolians.
Eternal Mongolia is an initiative of Enduring Earth, an ambitious collaboration between The Nature Conservancy, The Pew Charitable Trusts, World Wildlife Fund (WWF) and ZOMALAB that works in partnership with nations and communities as they accelerate and amplify conservation for a more sustainable, prosperous future for people and planet.
“To address the dual climate and biodiversity crises we must catalyze action at scale and ensure that people and livelihoods are at the center of the solution,” said Jennifer Morris, CEO of The Nature Conservancy and Board Chair of Enduring Earth.
Eternal Mongolia anticipates key financial support from Legacy Landscapes Fund. Eternal Mongolia initiatives would not be possible without philanthropic support from Jennifer Speers, Pamela Tanner Boll, The Jeremy and Hannelore Grantham Environmental Trust, Joanna & Stuart Brown, The Lorinet Foundation, China Global Conservation Fund, Sabra Turnbull & Clifford Burnstein, Trafigura Foundation, Margaret A. Cargill Philanthropies, Arcadia, Fondation Hans Wilsdorf, The Gallogly Family Foundation, and Robert W. Wilson Charitable Trust.
The full version of this press release with more information and additional quotes, including those from the Government of Mongolia, can be found at www.nature.org/en-us/newsroom/eternal-mongolia-pfp-announcement/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240421544883/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
